Global access to point-of-care CD4 devices and tests is under threat

Access to long-acting medicines will be key to meeting global HIV prevention and treatment targets.

In 2020, around 1.5 million people were newly infected with HIV. Global targets endorsed at the World Health Assembly 2022 aim to reduce new HIV infections from 1.5 million to under 370,000 by 2025 and under 335,000 by 2030. In order ...

CSO letter to ViiV on access to HIV PrEP drug cabotegravir

Diagnostic and treatment checklist for the management of HIV and advanced HIV disease in outpatient settings

Liposomal amphotericin B is a lifesaving treatment for several diseases. Collaborative work among stakeholders is essential to overcome persistent access barriers.

MSF statement at World Health Assembly Special Session on COVID-19, calling for people-centred, equitable, inclusive, open and transparent process.

This Strategic Framework sets out the case for a re-invigorated global drive to end cryptococcal meningitis deaths by 2030, as part of a broader drive to end all HIV-related deaths, and outlines what essential programmatic elements are ...

This Issue Brief analyses new developments in the access challenges to current and future ARVs and other critical medicines for the treatment of HIV and opportunistic infections that are responsible for the majority of HIV-related ...

In a joint letter, MSF and several concerned groups and individuals addressed Dr. Anthony Fauci, the head of the US National Institute of Allergy and Infectious Diseases (NIAID), asking that NIAID not grant exclusive rights in a HIV ...

AIDS related mortality remains high - 770,000 deaths in 2018 - and has hardly declined in recent years. This report, compiled by MSF, presents data from the AHD dashboard initiated by the HIV Advanced Disease Consortium (HIV-ADC).

This report examines the barriers to preventing new paediatric HIV infections and to providing timely and optimal treatment where we have failed to prevent transmission.

After a decade of strong commitments to fight the twin epidemics of HIV and tuberculosis (TB), a decline in international funding and the rapid shifting of the financial burden to affected countries is in danger of reversing lifesaving ...

This issue brief analyses access barriers to affordable, lifesaving diagnostics and treatments for HIV and OIs, including adult and paediatric formulations of dolutegravir – a highly effective and tolerable HIV integrase inhibitor that ...